Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin

Mary Kay Koenig, Adelaide A Hebert, Joan Roberson, Joshua Samuels, John Slopis, Audrey Woerner, Hope Northrup, Mary Kay Koenig, Adelaide A Hebert, Joan Roberson, Joshua Samuels, John Slopis, Audrey Woerner, Hope Northrup

Abstract

Background and objectives: Facial angiofibromas are disfiguring facial lesions, present in up to 80% of patients with tuberous sclerosis complex. Recent elucidation of the complex cell signaling pathways that are disrupted in tuberous sclerosis indicates that rapamycin may be successful in alleviating the appearance of these lesions. The objectives of the current study were to evaluate the safety of topically applied rapamycin in patients with tuberous sclerosis complex and to determine its potential effectiveness in treatment of facial angiofibromas.

Patients and methods: The study was a prospective, randomized, double-blind, placebo-controlled study performed at the University of Texas Health Science Center at Houston. Study subjects were recruited from the patient populations at the University of Texas Tuberous Sclerosis Center of Excellence. All subjects were over the age of 13 years and had a diagnosis of tuberous sclerosis complex. Subjects were excluded if they were using any form of rapamycin or if they were pregnant. Study subjects applied the study product to their facial angiofibromas nightly for a duration of 6 months. The investigational product contained one of three doses of rapamycin compounded with Skincerity®: (i) no rapamycin; (ii) 1 mg of rapamycin per 30 cc (0.003%); or (iii) 5 mg of rapamycin per 30 cc (0.015%). Plasma rapamycin concentrations were measured monthly to test for systemic absorption. Complete blood counts were performed monthly to test for anemia, neutropenia, or thrombocytopenia. Upon completion of the trial, subjects were asked if the formulation had improved the appearance of their facial angiofibromas.

Results: Twenty-three subjects completed the study. There was no detectable systemic absorption of rapamycin (all blood concentrations were <1.0 ng/mL). There were no significant changes in white blood cell, red blood cell, or platelet counts. Seventy-three percent of subjects in the treatment arms versus 38% of subjects in the placebo arm reported a subjective improvement in the appearance of their facial angiofibromas.

Conclusion: The application of low-dose topical rapamycin (0.003-0.015%) to the face can safely decrease the appearance of facial angiofibromas in patients with tuberous sclerosis complex.

Trial registration: ClinicalTrials.gov Identifier: NCT01031901.

Figures

Table I
Table I
Inclusion and exclusion criteria for study participation
Table II
Table II
Patient demographic data
Fig 1
Fig 1
Study subject (a) prior to therapy and (b) following 6 months of treatment with topical rapamycin. The subject reported complete resolution of his facial angiofibromas.

References

    1. Schwartz R.A., Fernandez G., Kotulska K., et al. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57:189–202. doi: 10.1016/j.jaad.2007.05.004.
    1. Kane Y. The “bumps” on my face. J Am Acad Dermatol. 2004;51:S11–2. doi: 10.1016/j.jaad.2004.01.016.
    1. El-Musa K.A., Shehadi R.S., Shehadi S. Extensive facial adenoma sebaceum: successful treatment with mechanical dermabrasion: case report. Brit J Plast Surg. 2005;58:1143–7. doi: 10.1016/j.bjps.2005.04.021.
    1. Finch T.M., Hindson C., Cotterill J.A. Successful treatment of adenoma sebaceum with the potassium titanyl phosphate laser. Clin Exp Dermatol. 1998;23:201–3. doi: 10.1046/j.1365-2230.1998.00371.x.
    1. Hori K., Soejima K., Nozaki M., et al. Treatment of facial angiofibromas of tuberous sclerosis using cultured epithelial autografts. Ann Plast Surg. 2006;57:415–7. doi: 10.1097/01.sap.0000221621.34715.21.
    1. Kaufman A.J., Grekin R.C., Geisse J.K., et al. Treatment of adenoma sebaceum with the copper vapor laser. J Am Acad Dermatol. 1995;33:770–4. doi: 10.1016/0190-9622(95)91814-0.
    1. Papadavid E., Markey A., Bellaney G., et al. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Brit J Plast Surg. 2002;147:337–42.
    1. Verheyden C.N. Treatment of the facial angiofibromas of tuberous sclerosis. Plast Reconstr Surg. 1996;98:777–83. doi: 10.1097/00006534-199610000-00003.
    1. Bittencourt R.C., Huilgol S.C., Seed P.T., et al. Treatment of angiofibromas with scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up. J Am Acad Dermatol. 2001;45:731–5. doi: 10.1067/mjd.2001.116223.
    1. Li S., Takeuchi F., Wang J., et al. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamaratomas. PNAS. 2008;105:3539–44. doi: 10.1073/pnas.0712397105.
    1. Darling T.N. Hamartomas and tubers from defects in harmartin-tuberin. J Am Acad Dermatol. 2004;51:S9–11. doi: 10.1016/j.jaad.2004.01.009.
    1. Bissler J.J., McCormack F.X., Young L.R., et al. Rapamycin for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl J Med. 2008;358:140–51. doi: 10.1056/NEJMoa063564.
    1. Franz D.N., Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:490–8. doi: 10.1002/ana.20784.
    1. Koenig M.K., Butler I.J., Northrup H. Regression of subependymal giant cells astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23:1238–9. doi: 10.1177/0883073808321764.
    1. Glasgow C.G., Steagall W.K., Taveira-DaSilva A., et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Resp Med. 2010;104:S45–58. doi: 10.1016/j.rmed.2010.03.017.
    1. Paghdal K.V., Schwartz R.A. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol. 2007;57:1046–50. doi: 10.1016/j.jaad.2007.05.021.
    1. Roach E.S., DiMario F.J., Kandt R.S., et al. Tuberous sclerosis consensus conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol. 1999;14:401–7. doi: 10.1177/088307389901400610.
    1. Foster R.S., Bint L.J., Halbert A.R. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53:52–6. doi: 10.1111/j.1440-0960.2011.00837.x.
    1. Truchuelo T., Diaz-Ley B., Rios L., et al. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol Online J. 2012;18:15.
    1. Wataya-Kaneda M., Tanaka M., Nakamura A., et al. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol. 2012;148:138–9. doi: 10.1001/archderm.148.1.138.
    1. DeKlotz C.M., Ogram A.E., Singh S., et al. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol. 2011;147:1116–7. doi: 10.1001/archdermatol.2011.254.
    1. Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma. J Eur Acad Dermatol Venereol. Epub 2011 Aug 11
    1. Valeron-Almazan P., Vitiello M., Abuchar A., et al. Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis. Actas Dermosifiliogr. 2012;103:165–6. doi: 10.1016/j.ad.2011.02.019.
    1. Mutizwa M.M., Berk D.R., Anadkat M.J. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mg mL−1) in two patients with tuberous sclerosis. Br J Dermatol. 2011;165:922–3. doi: 10.1111/j.1365-2133.2011.10476.x.
    1. Wataya-Kaneda M., Tanaka M., Nakamura A., et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165:912–6. doi: 10.1111/j.1365-2133.2011.10471.x.
    1. Kaufman McNamara E., Curtis A.R., Fleischer A.B., Jr Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat. 2012;23:46–8. doi: 10.3109/09546634.2010.489598.
    1. Haemel A.K., O’Brian A.L., Teng J.M. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715–8. doi: 10.1001/archdermatol.2010.125.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa